Our drug injury lawyers are available to investigate Xarelto® lawsuits for people who were treated with the drug and who suffered serious side effects such as internal bleeding. To schedule a free review of your case, contact us today.
The anti-clotting drug Xarelto® may increase the risk of serious, potentially fatal bleeding events in some patients, according to a new study. The study, which was funded by Johnson & Johnson, has raised some serious concerns.
According to researchers from Australia, Xarelto® presents less of a risk of bleeding in the brain than its competitor Coumadin® (warfarin) when given to patients with a common heart problem known as atrial fibrillation. But, the study also showed that Xarelto®, like a similar drug Pradaxa® (dabigatran), may cause more serious bleeding events that could be difficult to treat.
Pradaxa® has raised some concerns lately after being linked to several internal bleeding events in patients. And now that it has come out the Xarelto® may have similar risks, attention has turned to this drug as well. The U.S. Food and Drug Administration (FDA) announced that it is evaluating bleeding events in patients who were treated with Pradaxa® to determine whether the risks outweigh the benefits of the drug.
Internal bleeding is a serious complication that can lead to death. Patients being treated with
Xarelto® or similar drugs such as Pradaxa® should be aware of the symptoms of internal bleeding and should seek medical attention right away if they show the following signs:
Potential Xarelto® lawsuits can be investigated by our drug injury lawyers. If you or someone you love has experienced complications after receiving this anticoagulant, contact us today and schedule a free evaluation of your case.